ReviewMikrochimica acta2022
Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2.
Review in Mikrochimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Highly sensitive fluorescent lateral flow immunoassay based on core-shell PS@Dip@SiOMikrochimica acta · 2026Article
- Smartphone-Based Peptide Nucleic Acid (PNA) Probe-Assisted Potentiometric Biosensor for Point-of-Care Testing of SARS-CoV-2 Nucleic Acid.Analytical chemistry · 2026Article
- Article
- Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.Small methods · 2025Review
- New Frontiers for the Early Diagnosis of Cancer: Screening miRNAs Through the Lateral Flow Assay Method.Biosensors · 2025Review
- Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials.Nano convergence · 2024Review
- Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections.MethodsX · 2023Article
- Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care.Bioengineering (Basel, Switzerland) · 2023Article
- Comparison of a Blood Self-Collection System with Routine Phlebotomy for SARS-CoV-2 Antibody Testing.Diagnostics (Basel, Switzerland) · 2022Article
- Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics.Bioengineering (Basel, Switzerland) · 2022Review
- Advances in the use of nanomaterials for nucleic acid detection in point-of-care testing devices: A review.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
This review focuses on critical scientific barriers that the field of point-of-care (POC) testing of SARS-CoV-2 is facing and possible solutions to overcome these barriers using functional nucleic acid (FNA)-based technology. Beyond the summary of recent advances in FNA-based sensors for COVID-19 diagnostics, our goal is to outline how FNA might serve to overcome the scientific barriers that currently available diagnostic approaches are suffering. The first introductory section on the operationalization of the COVID-19 pandemic in historical view and its clinical features contextualizes essential SARS-CoV-2-specific biomarkers. The second part highlights three major scientific barriers for POC COVID-19 diagnosis, that is, the lack of a general method for (1) designing receptors of SARS-CoV-2 variants; (2) improving sensitivity to overcome false negatives; and (3) signal readout in resource-limited settings. The subsequent part provides fundamental insights into FNA and technical tricks to successfully achieve effective COVID-19 diagnosis by using in vitro selection of FNA to overcome receptor design barriers, combining FNA with multiple DNA signal amplification strategies to improve sensitivity, and interfacing FNA with portable analyzers to overcome signal readout barriers. This review concludes with an overview of further opportunities and emerging applications for FNA-based sensors against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.